8,859 Research products, page 1 of 886
Loading
- Publication . Article . 2014Open AccessAuthors:Societies Editorial Office;Societies Editorial Office;
doi: 10.3390/soc4010125
Publisher: MDPI AGThe editors of Societies would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2013. [...]
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2018Open AccessAuthors:Andrew Spencer; Suzanne Lentzsch; Katja Weisel; Hervé Avet-Loiseau; Tomer M Mark; Ivan Spicka; Tamás Masszi; Birgitta Lauri; Mark-David Levin; Alberto Bosi; +27 moreAndrew Spencer; Suzanne Lentzsch; Katja Weisel; Hervé Avet-Loiseau; Tomer M Mark; Ivan Spicka; Tamás Masszi; Birgitta Lauri; Mark-David Levin; Alberto Bosi; Vania Hungria; Michele Cavo; Je-Jung Lee; Ajay K. Nooka; Hang Quach; Cindy Lee; Wolney Barreto; Paolo Corradini; Chang-Ki Min; Emma C. Scott; Asher Chanan-Khan; Noemi Horvath; Marcelo Capra; Meral Beksac; Roberto Ovilla; Jae Cheol Jo; Ho Jin Shin; Pieter Sonneveld; David Soong; Tineke Casneuf; Christopher Chiu; Himal Amin; Ming Qi; Piruntha Thiyagarajah; A. Kate Sasser; Jordan M. Schecter; Maria-Victoria Mateos;Publisher: Ferrata Storti Foundation (Haematologica)Countries: Netherlands, Italy
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0–27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P12, ≤6, or >6 months), or cytogenetic risk. Minimal residual disease–negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. Trial registration: clinicaltrials.gov identifier: 02136134.
Substantial popularitySubstantial popularity In top 1%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2017Open AccessAuthors:Alena Skálová; Michal Michal; Roderick H.W. Simpson;Alena Skálová; Michal Michal; Roderick H.W. Simpson;Publisher: Springer Science and Business Media LLC
This review concentrates on three salivary gland tumors that have been accepted in the recent literature as new neoplastic entities: mammary analog secretory carcinoma (MASC), sclerosing polycystic adenoma (SPA) and cribriform adenocarcinoma of tongue and other minor salivary glands (CAMSGs). MASC is a distinctive low-grade malignant salivary cancer that harbors a characteristic chromosomal translocation, t(12;15) (p13;q25) resulting in an ETV6–NTRK3 fusion. SPA is a rare lesion often mistaken histologically for low-grade salivary carcinoma. Previously thought to be a reactive fibroinflammatory process, but recent evidence of clonality, recurrences in up 30%, and dysplastic foci suggest it may be truly neoplastic. CAMSG is a distinct tumor entity that differs from polymorphous low-grade adenocarcinoma (PLGA) by location (ie, most often arising on the tongue), by prominent nuclear clearing, alterations of the PRKD gene family and clinical behavior with frequent metastases at the time of presentation of the primary tumor. Early metastatic disease seen in most cases of CAMSG associated with indolent behavior makes it a unique neoplasm among all low-grade salivary gland tumors. Salivary glands may give rise to a wide spectrum of different tumors. They are often diagnostically challenging as morphological features often overlap between different entities. Although conventional morphology in combination with immunohistochemical findings still provide the most important clues for diagnosis, recent advances in molecular pathology offer new diagnostic tools in investigating the differential diagnosis, as well as providing potentially valuable prognostic indicators. In the last two decades, several new salivary gland tumor entities have been described, namely MASC, SPA and CAMSGs.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2019Open AccessAuthors:Morad Aaboud; Alexander Kupco; Stefan Schmitt; Ahmed Bassalat; Matej Melo; Marjorie Shapiro; Grigore Tarna; Till Eifert; Maximiliano Sioli; Nello Bruscino; +816 moreMorad Aaboud; Alexander Kupco; Stefan Schmitt; Ahmed Bassalat; Matej Melo; Marjorie Shapiro; Grigore Tarna; Till Eifert; Maximiliano Sioli; Nello Bruscino; Toshi Sumida; Andrei Snesarev; Edson Carquin; Mohamad Kassem Ayoub; Yanlin Liu; Paolo Mastrandrea; Liaoshan Shi; José Maneira; Daniela Bortoletto; Tatsuya Masubuchi; Danilo Enoque Ferreira de Lima; Joaquin Poveda; Krzysztof Korcyl; Tatiana Lyubushkina; Christian Grefe; Konstantin Toms; Alberto Valero; Antonio Policicchio; Efe Yigitbasi; Sergey Karpov; Pavol Strizenec; Leigh Schaefer; Marcel Vos; Evelin Meoni; Caterina Doglioni; Masahiro Kuze; Katherine Pachal; Davide Costanzo; Giuliano Gustavino; Mateusz Dyndal; Daniele Zanzi; Alexey Ezhilov; Miguel Arratia; David Paul Yallup; Alena Loesle; Liron Barak; Giuseppe Iacobucci; Benedetto Gorini; Harald Fox; Sergio Grancagnolo; Hok Chuen Cheng; Nico Madysa; Joshua Wyatt Smith; Alessandro Tricoli; Michele Faucci Giannelli; Jana Faltova; Stewart Patrick Swift; Mark Oreglia; Francesco De Lorenzi; Ozan Arslan; Hatice Duran Yildiz; Nicolo Vladi Biesuz; Juan Terron; Stefano Camarda; Maximilian Swiatlowski; Nikolaos Konstantinidis; Osamu Jinnouchi; Hartmut Sadrozinski; Yuya Kano; Daniel Camarero Munoz; Fangzhou Zhang; Manuella Vincter; Markus Elsing; Antony Fray; Paolo Massarotti; Lorenzo Rossini; Giulia Di Gregorio; Francois Corriveau; Karel Smolek; Petr Tas; Ana Rosario Cueto Gomez; Brian Petersen; Victor Solovyev; Bijan Haney; Sinead Farrington; Mauro Villa; Vladimir Cindro; Philip Sommer; Shunsuke Honda; M. Franklin; Yang Qin; Knut Zoch; Susumu Oda; Christian Gutschow; Masahiko Saito; Eva Hansen; Matt Zhang; Adam Bailey; Tomas Jakoubek; Matthias Danninger; Serhat Istin; Mazuza Ghneimat; Goeran Jarlskog; Alessandro De Salvo; Yury Smirnov; Alejandro Alonso; Emma Winkels; Emmanuel Le Guirriec; Andrey Ryzhov; Pier-Olivier Deviveiros; Andres Pacheco Pages; Michael Begel; Allen Mincer; Ljiljana Morvaj; Grazia Cabras; Catalin Agheorghiesei; Roland Jansky; Uwe Bratzler; Claire David; Maria Josefina Alconada Verzini; Romain Kukla; Pawel Klimek; Clara Troncon; Francesco Guescini; Juan Antonio Garcia Pascual; Chunhui Chen; Ivo van Vulpen; Elizaveta Shabalina; Guillaume Unal; Yu Zhang; Zhiqing Zhang; Karishma Sekhon; Gabriele Chiodini; Thorwald Klapdor-kleingrothaus; Frederik Ruehr; Liza Mijović; Harish Potti; Scott Snyder; Rostislav Konoplich; Sarah Heim; Giuseppe Lerner; Stefano Veneziano; Andrey Kiryunin; Laura Barranco Navarro; Leonid Serkin; Dengfeng Zhang; Sergei Smirnov; Babar Ali; Andrej Filipcic; Mario Lassnig; Liang Li; Jonathan Butterworth; Melissa Ridel; Geoffrey Mullier; Kun Liu; Christian Ohm; James Shank; Robert Astalos; Eram Rizvi; Eirik Gramstad; Steven Schramm; Yasuhiro Makida; Ana Paula Pereira Peixoto; Cristiano Alpigiani; Qi Zeng; Nabila Wahab Shaikh; Tibor Zenis; Fabio Cardillo; K. K. Gan; Steffen Henkelmann; Stefano Terzo; Ewelina Lobodzinska; Junji Tojo; Louise Heelan; Giancarlo Panizzo; Muhammad Alhroob; Hans Peter Beck; Katharine Leney; Ryan White; Paolo Camarri; Rafal Staszewski; Elena Rocco; John Rutherfoord; L. L. Ma; Giuseppe Avolio; Gianluca Alimonti; Yang Yang; Chaowaroj Wanotayaroj; Luca Colasurdo; Luc Goossens; Nadezda Proklova; Masato Aoki; Yasushi Nagasaka; Petr Andreevich Gorbounov; Simen Hellesund; Jens Weingarten; Marco Valente; Didier Ferrere; Ina Carli; Sofia Chouridou; Hideyuki Oide; Marcello Bindi; Sandro Palestini; Andrea Ventura; Anna Kaczmarska; Tomas Davidek; Monika Wielers; Yang Li; Domizia Orestano; Nico Giangiacomi; Garabed Halladjian; Alessandro La Rosa; Lawrence Lee; Yaquan Fang; Kevin Varvell; Nils-Arne Rosien; Andrew Pilkington; Claus Goessling; Trine Poulsen; Enrico Junior Schioppa; Arnaud Lucotte; Laura Gonella; Esteban Fullana Torregrosa; Katsuo Tokushuku; Ruchika Nayyar; Rosa Simoniello; Tobias Golling; Kristin Lohwasser; Iouri Naryshkin; Vasiliki Kouskoura; Weiming Yao; Simone Michele Mazza; Patrawan Pasuwan; Frank Ellinghaus; Steven Goldfarb; Valerie Susanne Lang; Arwa Bannoura; Judita Mamuzic; Pavel Staroba; Marcela Mikestikova; Tatyana Kharlamova; Emily McDonald; Jian Cong Zeng; Francisco Alonso; Chris Hays; Craig Sawyer; Pawel Bruckman de Renstrom; Carlos Lacasta; Paolo Morettini; Wolfgang Walkowiak; Kyle Cranmer; Kuan-yu Lin; Joseph Reichert; Vincenzo Canale; Saskia Falke; Krzysztof Wozniak; Claire Antel; Joern Lange; Sandro De Cecco; Silvia Biondi; Julien Donini; Bernhard Meirose; James Robinson; Calin Alexa; Sophie Trincaz-Duvoid; Giada Mancini; Carl Suster; Antonio Ereditato; Wade Cameron Fisher; Marina Rotaru; Aidan Grummer; Petr Balek; Nicolas Morange; Per Johansson; Massimo Della Pietra; Riccardo-Maria Bianchi; Alison Lister; Christos Leonidopoulos; Laura Perini; Dirk Sammel; Giuseppe Callea; Miaoran Lu; Marc-Andre Pleier; Vitaliano Chiarella; Mariusz Przybycien; Petr Hamal; Artur Trofymov; Antoine Marzin; Trisha Farooque; Alan Litke; Frank Winklmeier; Mihai Caprini; Christian Weiser; Florencia Luciana Castillo; Helmut Wolters; Iacopo Vivarelli; Jahred Adelman; Wendy Taylor; Ning Zhou; Koji Terashi; Fabio Cerutti; Paul Glaysher; Emma Torró Pastor; Thomas Trefzger; Alexey Zhemchugov; Baptiste Ravina; Rachel Maria Avramidou; Stephen Hillier; Mohammed Ezzi; Sten Hellman; Wing Sheung Chan; Phillip Urquijo; Vakhtang Kartvelishvili; Lorenzo Massa; Benedict Tobias Winter; Fabian Thiele; Oscar Estrada Pastor; Daniel Lellouch; Aliaksei Hrynevich; Spyridon Argyropoulos; Sergey Senkin; Frederic Deliot; Takuya Nobe; Farida Fassi; Sahal Yacoob; Giuseppe Francesco Tartarelli; Anton Wolf; Farid Ould-Saada; Rachik Soualah; Gilberto Giugliarelli; Wenhao Xu; Artem Maevskiy; Christoph Falk Anders; Roberto Di Nardo; Marcus De Beurs; Marilea Reale; Michal Svatos; Yulia Rodina; Dimitrii Krasnopevtsev; Pingchuan Zhao; Marino Romano; Liang Guan; Peter Loch; Giovanna Cottin; Weimin Song; Heather Gray; Martin Nagel; Stephen Burke; Alexander Held; Paul Thompson; Edward Moyse; Jyoti Prakash Biswal; Jorn Grosse-Knetter; Kohei Yorita; Arno Straessner; Elizabeth Gallas; Evgenia Cheremushkina; Evelyn Thomson; Sergio Calvente Lopez; Oxana Smirnova; Bjarne Stugu; Adam Trzupek; Yoram Rozen; Fabien Jeanneau; Sau Lan Wu; Nikita Smirnov; Ryu Sawada; Michel Lefebvre; Ondrej Penc; Alexandra Tudorache; Nicholas Stuart Dann; Tomasz Bold; Ismet Siral; Andreas Kugel; Andrew Mehta; Arnaud Duperrin; Archil Durglishvili; Craig Buttar; Soumya Mohapatra; Claude Leroy; Dominik Derendarz; Pavel Tsiareshka; Trevor Vickey; Claire Gwenlan; Sergey Peleganchuk; Kristian Gregersen; Andreas Warburton; Andrew Blue; Marco Rimoldi; Peter Johannes Falke; Vadim Bednyakov; Fernando Barreiro; Peter Watkins; Mihail Chizhov; Veronica Fabiani; Santiago González de la Hoz; Xiangyang Ju; Klaus Moenig; Sylvain Tisserant; Alessandra Camplani; Krisztian Peters; David DeMarco; Julien Caudron; Ziyu Guo; Michal Marcisovsky; Ming Chung Chu; Juerg Beringer; Edoardo Maria Farina; Hugh Williams; Patrick Czodrowski; Elias Coniavitis; Diane Cinca; Juan Antonio Aguilar Saavedra; Mykhailo Lisovyi; Aaron White; Michal Suk; Michele Livan; Tamar Djobava; Ladislav Chytka; Pierre-Antoine Delsart; Ivan Sykora; Enrico Tassi; Iwona Grabowska-Bold; Sara Alderweireldt; Luigi Longo; Helio Takai; Patricia Conde Muiño; Johannes Erdmann; Anna Lipniacka; Serkant Ali Cetin; Fabrizio Trovato; Javier Montejo Berlingen; Laurent Schoeffel; Asma Hadef; Jiri Hejbal; Alexandros Marantis; Jean-Francois Arguin; Stefan Richter; Cheuk Yee Lo; Magda Anna Chelstowska; Nicola Orlando; Roger Jones; Marc Escalier; Salvatore Bruno; Giulia Gonella; Sarah Jones; Elisabetta Pianori; Maciej Trzebinski; Nicolas Berger; Guenter Duckeck; Dominik Duda; Sebastien Prince; Alison Elliot; Zuzana Rurikova; Khilesh Pradip Mistry; Jaroslav Guenther; Robert Stanek; Diego Casadei; Minghui Liu; Yuta Okazaki; Calliope Louisa Sotiropoulou; Tomoya Iizawa; Victor Araujo Ferraz; Vladimir Tikhomirov; Umberto De Sanctis; Per Edvin Sidebo; Eftychia Tzovara; Dale Charles Abbott; Werner Spolidoro Freund; Alessandro Calandri; Remi Lafaye; James Broughton; Ralf Hertenberger; Giacomo Artoni; Christophe Raymond Goudet; Oliver Ricken; Patrick Rieck; Sandrine Laplace; Sergey Burdin; Rotem Barnea; Ewan Hill; Andre Sopczak; Emmanuel Sauvan; Dominik Krauss; Jonas Strandberg; Salah-eddine Dahbi; Antonios Leisos; Simone Monzani; Kathleen Whalen; Francesco Giuli; Roman Lysak; Paolo Giromini; Leszek Adamczyk; Jason Nielsen; Thomas Koffas; Marcella Bona; Beojan Stanislaus; Gianluca Introzzi; Natascha Savic; Wasikul Islam; Otmar Biebel; Fares Djama; Federico Sforza; Jonathan Bortfeldt; Eleni Myrto Asimakopoulou; Yun Tian; Romain Madar; Phillip Allport; Nicolas Ellis; Jan Godlewski; Jiri Kroll; Benjamin Trocmé; Stephen Watts; Will Davey; Yann Coadou; Wladyslaw Dabrowski; Cristinel Diaconu; Clement Helsens; Hongbo Zhu; Swagato Banerjee; Stephen Lloyd; Alessandra Betti; Peter van Gemmeren; Alberto Aloisio; Vincent Pascuzzi; Driss Benchekroun; Martin Aleksa; Ilija Vukotic; Evgeniy Khramov; James Monk; Michel Vetterli; Marco Vanadia; Takahiko Kondo; Bruno Lenzi; Aleandro Nisati; Gerjan Bobbink; Paul Dervan; Stefania Spagnolo; Dave Charlton; Robert Les; Marcella Capua; Jochen Jens Heinrich; Valentina Tudorache; Stephen Jiggins; Kunlin Han; Shunsuke Adachi; Amy Selvi Tee; Giulio Aielli; Susana Cabrera Urbán; Paolo Calafiura; Pavel Starovoitov; Lorenzo Feligioni; Vladimir Sulin; Meghan Frate; Camilla Di Donato; Ludovic Michel Scyboz; Bakar Chargeishvili; Eric Edward Corrigan; Kendall Reeves; Gideon Bella; Alexandre Rozanov; M. J. Shochet; Ewa Stanecka; Norman Gee; Efstathios Karentzos; Katharina Behr; Jozsef Toth; Peter Onyisi; Remi Zaidan; Tim Michael Heinz Wolf; Fang-ying Tsai; Irinel Caprini; Abraham Seiden; Martina Laura Ojeda; Gonzalo Enrique Orellana; Marcos Vinicius Silva Oliveira; Fabrizio Napolitano; Arka Santra; Jan Kretzschmar; Stefano Rosati; Janet Dietrich; Gen Kawamura; Angel Campoverde; Oleg Brandt; Antinea Guerguichon; James Walder; Torsten Paul Ake Åkesson; Namig Javadov; Milene Calvetti; Louis Guillaume Gagnon; Paul Jackson; Matteo Franchini; Maurizio De Santis; Christian Schmitt; Ren-Jie Wang; Hasko Stenzel; Sebastian Grinstein; Aidan Robson; Paolo Sabatini; Flavia De Almeida Dias; Marco Delmastro; Jeroen Schouwenberg; Song-Ming Wang; Danijela Bogavac; Mikhail Levchenko; Paul Miyagawa; Nataliia Zakharchuk; Valerio Dao; Kerstin Jon-And; Laurent Serin; Andrea Coccaro; Milos Lokajicek; Christos Vergis; Jiangyong Jia; Yusheng Wu; Mathieu Benoit; Georges Azuelos; Markus Cristinziani; Soshi Tsuno; Athanasios Manousos; Yee Chinn Yap; Jos Vermeulen; Sune Jakobsen; Philipp Mogg; Marek Palka; Carl Gwilliam; Osamu Sasaki; Roberto Iuppa; Yohei Yamaguchi; Anjishnu Bandyopadhyay; Philipp Horn; Syed Haider Abidi; Nishu Nishu; Jose Guillermo Panduro Vazquez; Ilia Ravinovich; Uladzimir Kruchonak; Alessia Murrone; Gerald Oakham; Annick Lleres; Nathalie Besson; Matthias Saimpert; Janusz Chwastowski; Marco Sessa; Takanori Kono; Jens Janssen; Antonio Onofre; Arthur Eugen Bolz; Nikolina Ilic; Jolanta Olszowska; Elisabeth Schopf; Vakhtang Tsulaia; Nicolin Govender; Martine Bosman; Danuta Kisielewska; Ilkay Turk Cakir; Victor Maleev; Michele Pinamonti; Marta Losada; Marija Vranjes Milosavljevic; Lee Sawyer; Joaquin Hoya; Caterina Marcon; Victor Kukhtin; Georges Aad; Hyungsuk Son; Michaela Queitsch-Maitland; George Redlinger; Fred Wickens; Ki Lie; Marcel Weirich; Matteo Negrini; Filipe Veloso; Sabrina Groh; Lucia Masetti; Thomas Billoud; Akshat Puri; Francesco Maria Follega; Vadim Gratchev; Tadej Novak; Nektarios Benekos; Miguel Villaplana Perez; Henri Bachacou; Alessandro Cerri; Massimo Lazzaroni; Edward Diehl; Jan-Hendrik Arling; Julie Kirk; Andrey Kamenshchikov; Rui Wang; Ruggero Turra; Andrea Knue; Steven Worm; Hajime Nanjo; Christian Oliver Sander; Eduard Simioni; Hongtao Yang; Matteo Scornajenghi; Valerio Vercesi; Lewis James Armitage; Khalil Bouaouda; Sigve Haug; Christina Potter; Fuqiang Wang; Benoit Lefebvre; Aparajita Dattagupta; Sourav Sen; Hans-Christian Schultz-Coulon; Yuji Yamazaki; Peter Berta; Murrough Landon; Fabrice Hubaut; Leonid Kurchaninov; Dimitrios Iliadis; Alexey Anisenkov; Yanjun Tu; Richard Keeler; Stanislav Nemecek; Frank Filthaut; Guennadi Borissov; Amal Vaidya; Laurent Chevalier; Veronika Magerl; Paola Giannetti; Orhan Cakir; Tomohiro Yamazaki; Javier Llorente Merino; Geoffrey Taylor; Anatoli Romaniouk; Alberto Stabile; Stamatios Gkaitatzis; Evgenii Baldin; Serhat Oerdek; Paul Mircea Gravila; Nikola Makovec; Marzieh Bahmani; Konstantinos Bachas; Konstantinos Nikolopoulos; Oliver Majersky; Elliot Reynolds; Troels Petersen; Oldrich Kepka; Maximilian Hils; Francesco Ragusa; Haifeng Li; Stephen Gibson; Aimilianos Koulouris; Teng Jian Khoo; Alexi Gongadze; Robert McPherson; Daniel Muenstermann; Jeffrey David Shahinian; Bruce Yabsley; Kilian Rosbach; Philipp Stolte; Tamara Vazquez Schroeder; Royer Edson Ticse Torres; Andrew D. Hamilton; Siqi Yang; Claudia Glasman; Tigran Mkrtchyan; Theodoros Alexopoulos; Paul Philipp Gadow; Leonor Cerda Alberich; Riccardo Vari; Debarati Roy; Tomas Dado; Dave Britton; Vojtech Pleskot; Yuri Kulchitsky; Margherita Primavera; Konstantinos Ntekas; Minyu Feng; Thorsten Wengler; Deepak Kar; Jianming Qian; Frank Merritt; Shyam Balaji; Lydia Brenner; Xin Wu; Nikiforos Nikiforou; Jiri Chudoba; Andrea Formica; Michal Dubovsky; Christos Anastopoulos; James Mueller; Francesca Ungaro; Jonathan David Bossio Sola; Elvedin Tahirovic; Torre Wenaus; Giulio Cornelio Grossi; Abhishek Sharma; Evangelos Kourlitis; Craig Wiglesworth; Antonio Salvucci; Bingxuan Liu; Pascal Pralavorio; Valerio Ippolito; Laura Fabbri; Lydia Roos; Stefania Xella; Radek Novotny; David Lynn; Elizabeth Brost; Martin White; Andrzej Olszewski; Nenad Vranjes; Lamberto Luminari; Peter Kodys; Tim Adye; John Baines; Lara Katharina Schildgen; Adriaan Koenig; Tristan Beau; Lily Asquith; Maria Smizanska; Mattias Ellert; Zoya Karpova; Othmane Rifki; Gunnar Jakel; Walter Hopkins; Werner Wiedenmann; Kazunori Hanagaki; Eric Lancon; Andrzej Smykiewicz; Christine Kourkoumelis; Jana Schaarschmidt;Publisher: American Physical Society (APS)Project: NSERC
A measurement of the associated production of a top-quark pair (tt) with a vector boson (W, Z) in proton-proton collisions at a center-of-mass energy of 13 TeV is presented, using 36.1 fb-1 of integrated luminosity collected by the ATLAS detector at the Large Hadron Collider. Events are selected in channels with two same- or opposite-sign leptons (electrons or muons), three leptons or four leptons, and each channel is further divided into multiple regions to maximize the sensitivity of the measurement. The ttZ and ttW production cross sections are simultaneously measured using a combined fit to all regions. The best-fit values of the production cross sections are σttZ=0.95±0.08stat±0.10syst pb and σttW=0.87±0.13stat±0.14syst pb in agreement with the Standard Model predictions. The measurement of the ttZ cross section is used to set constraints on effective field theory operators which modify the ttZ vertex.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2015Open AccessAuthors:Jiří Vohánka; Mir Faizal;Jiří Vohánka; Mir Faizal;Publisher: American Physical Society (APS)
In this paper, we will analyze three-dimensional supersymmetric Yang-Mills theory coupled to matter fields in $SIM(1)$ superspace formalism. The original theory which is invariant under the full Lorentz group has $\mathcal{N}=1$ supersymmetry. However, when we break the Lorentz symmetry down to $SIM(1)$ group, the $SIM(1)$ superspace will break half the supersymmetry of the original theory. Thus, the resultant theory in $SIM(1)$ superspace will have $\mathcal{N}=1/2$ supersymmetry. This is the first time that $\mathcal{N}=1$ supersymmetry will be broken down to $\mathcal{N}=1/2$ supersymmetry, for a three-dimensional theory, on a manifold without a boundary. This is because it is not possible to use nonanticommutativity to break $\mathcal{N}=1$ supersymmetry down to $\mathcal{N}=1/2$ supersymmetry in three dimensions.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2003Open AccessAuthors:Schellenberg, D; Armstrong Schellenberg, J R M; Mushi, A; Savigny de, D; Mgalula, L; Mbuya, C; Victoria, C.G.;Schellenberg, D; Armstrong Schellenberg, J R M; Mushi, A; Savigny de, D; Mgalula, L; Mbuya, C; Victoria, C.G.;Country: Tanzania (United Republic of)
Objective was to document the prevalence, age-distribution, and risk factors for anaemia in Tanzanian children less than 5 years old,thereby assisting in the development of effective strategies for controlling anaemia. Cluster sampling was used to identify 2417 households at random from four contiguous districts in south-eastern United Republic of Tanzania in mid-1999. Data on various social and medical parameters were collected and analysed. Blood haemoglobin concentrations (Hb) were available for 1979 of the 2131 (93%) children identified and ranged from 1.7 to 18.6 g/dl. Overall, 87% (1722) of children had an Hb <11 g/dl, 39% (775) had an Hb <8 g/dl and 3% (65) had an Hb <5 g/dl. The highest prevalence of anaemia of all three levels was in children aged 6–11 months, of whom 10% (22/226) had an Hb <5 g/dl. However, the prevalence of anaemia was already high in children aged 1–5 months (85% had an Hb <11 g/dl, 42% had an Hb <8 g/dl, and 6% had an Hb <5 g/dl). Anaemia was usually asymptomatic and when symptoms arose they were nonspecific and rarely identified as a serious illness by the care provider. A recent history of treatment with antimalarials and iron was rare. Compliance with vaccinations delivered through the Expanded Programme of Immunization (EPI) was 82% and was notassociated with risk of anaemia. Anaemia is extremely common in south-eastern United Republic of Tanzania, even in very young infants. Further implementation of the Integrated Management of Childhood Illness algorithm should improve the case management of anaemia. However, the asymptomatic nature of most episodes of anaemia highlights the need for preventive strategies. The EPI has good coverage of the target population and it may be an appropriate channel for delivering tools for controlling anaemia and malaria.
- Publication . Other literature type . Article . 2019Open AccessAuthors:Zdenka Ellederova; Sonia del Rincon; Marketa Koncicka; Andrej Susor; Michal Kubelka; Dahui Sun; Charles Spruck;Zdenka Ellederova; Sonia del Rincon; Marketa Koncicka; Andrej Susor; Michal Kubelka; Dahui Sun; Charles Spruck;Publisher: American Society for Microbiology
Cell division cycle (Cdc) kinase subunit (CKS) proteins bind cyclin-dependent kinases (CDKs) and play important roles in cell division control and development, though their precise molecular functions are not fully understood. Mammals express two closely related paralogs called CKS1 and CKS2, but only CKS2 is expressed in the germ line, indicating that it is solely responsible for regulating CDK functions in meiosis. Using cks2(−/−) knockout mice, we show that CKS2 is a crucial regulator of maturation-promoting factor (MPF; CDK1-cyclin A/B) activity in meiosis. cks2(−/−) oocytes display reduced and delayed MPF activity during meiotic progression, leading to defects in germinal vesicle breakdown (GVBD), anaphase-promoting complex/cyclosome (APC/C) activation, and meiotic spindle assembly. cks2(−/−) germ cells express significantly reduced levels of the MPF components CDK1 and cyclins A1/B1. Additionally, injection of MPF plus CKS2, but not MPF alone, restored normal GVBD in cks2(−/−) oocytes, demonstrating that GVBD is driven by a CKS2-dependent function of MPF. Moreover, we generated cks2(cks1/cks1) knock-in mice and found that CKS1 can compensate for CKS2 in meiosis in vivo, but homozygous embryos arrested development at the 2- to 5-cell stage. Collectively, our results show that CKS2 is a crucial regulator of MPF functions in meiosis and that its paralog, CKS1, must be excluded from the germ line for proper embryonic development.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . ArticleOpen Access EnglishPublisher: Published by Elsevier Inc.
- Publication . Preprint . 1995Open Access EnglishAuthors:Mares, J.; Friedman, E.; Gal, A.; Jennings, B. K.;Mares, J.; Friedman, E.; Gal, A.; Jennings, B. K.;Project: NSERC
Strong interaction level shifts and widths in $\Sigma^-$ atoms are analyzed by using a $\Sigma$ nucleus optical potential constructed within the relativistic mean field approach. The analysis leads to potentials with a repulsive real part in the nuclear interior. The data are sufficient to establish the size of the isovector meson--hyperon coupling. Implications to $\Sigma$ hypernuclei are discussed. Comment: 18 pages, RevTex, 4 uuencoded figures, subm. Nucl.Phys.A
- Publication . Article . 1997Open AccessAuthors:Graham J. Schapel; Sheila J. Wallace; Gillian S. Gordon;Graham J. Schapel; Sheila J. Wallace; Gillian S. Gordon;Publisher: Elsevier BV
A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales. Of 79 patient treatments with LTG and 86 with GVG, 42 patients were treated with add-on LTG, 52 with add-on GVG and 20 with both drugs simultaneously. A Kaplan-Meier curve, applied to each of the two index drugs, indicated that 71 and 62% of patients would be expected to continue taking LTG or GVG, respectively after 40 months. Improved seizure control (≥ 50%) at the time of audit was seen in 65% of LTG and 58% of GVG patient treatments for all epilepsy syndromes, but there was a higher proportion of patients with generalized epilepsy improved by LTG (28/41, 68%) than that improved by GVG (8/20, 40%), and only those with generalized epilepsy treated with LTG became seizure free (8/38, 21%). Similar proportions of patients discontinued LTG (16%) and GVG (15%) due to an adverse experience, but a higher proportion discontinued GVG (18%) compared with LTG (6%) because of lack of efficacy. This study supports the relative clinical effectiveness of LTG and GVG in the real world, where children with severe epilepsy are treated in clinical practice and serves to generate hypotheses to enable design of prospectively controlled trials, which should enable more rational use of these two drugs in the paediatric population with epilepsy.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.
8,859 Research products, page 1 of 886
Loading
- Publication . Article . 2014Open AccessAuthors:Societies Editorial Office;Societies Editorial Office;
doi: 10.3390/soc4010125
Publisher: MDPI AGThe editors of Societies would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2013. [...]
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2018Open AccessAuthors:Andrew Spencer; Suzanne Lentzsch; Katja Weisel; Hervé Avet-Loiseau; Tomer M Mark; Ivan Spicka; Tamás Masszi; Birgitta Lauri; Mark-David Levin; Alberto Bosi; +27 moreAndrew Spencer; Suzanne Lentzsch; Katja Weisel; Hervé Avet-Loiseau; Tomer M Mark; Ivan Spicka; Tamás Masszi; Birgitta Lauri; Mark-David Levin; Alberto Bosi; Vania Hungria; Michele Cavo; Je-Jung Lee; Ajay K. Nooka; Hang Quach; Cindy Lee; Wolney Barreto; Paolo Corradini; Chang-Ki Min; Emma C. Scott; Asher Chanan-Khan; Noemi Horvath; Marcelo Capra; Meral Beksac; Roberto Ovilla; Jae Cheol Jo; Ho Jin Shin; Pieter Sonneveld; David Soong; Tineke Casneuf; Christopher Chiu; Himal Amin; Ming Qi; Piruntha Thiyagarajah; A. Kate Sasser; Jordan M. Schecter; Maria-Victoria Mateos;Publisher: Ferrata Storti Foundation (Haematologica)Countries: Netherlands, Italy
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis based on treatment history and longer follow up is presented. After 19.4 (range: 0–27.7) months of median follow up, daratumumab plus bortezomib and dexamethasone prolonged progression-free survival (median: 16.7 versus 7.1 months; hazard ratio, 0.31; 95% confidence interval, 0.24-0.39; P12, ≤6, or >6 months), or cytogenetic risk. Minimal residual disease–negative rates were >2.5-fold higher with daratumumab across subgroups. The safety profile of daratumumab plus bortezomib and dexamethasone remained consistent with longer follow up. Daratumumab plus bortezomib and dexamethasone demonstrated significant clinical activity across clinically relevant subgroups and provided the greatest benefit to patients treated at first relapse. Trial registration: clinicaltrials.gov identifier: 02136134.
Substantial popularitySubstantial popularity In top 1%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2017Open AccessAuthors:Alena Skálová; Michal Michal; Roderick H.W. Simpson;Alena Skálová; Michal Michal; Roderick H.W. Simpson;Publisher: Springer Science and Business Media LLC
This review concentrates on three salivary gland tumors that have been accepted in the recent literature as new neoplastic entities: mammary analog secretory carcinoma (MASC), sclerosing polycystic adenoma (SPA) and cribriform adenocarcinoma of tongue and other minor salivary glands (CAMSGs). MASC is a distinctive low-grade malignant salivary cancer that harbors a characteristic chromosomal translocation, t(12;15) (p13;q25) resulting in an ETV6–NTRK3 fusion. SPA is a rare lesion often mistaken histologically for low-grade salivary carcinoma. Previously thought to be a reactive fibroinflammatory process, but recent evidence of clonality, recurrences in up 30%, and dysplastic foci suggest it may be truly neoplastic. CAMSG is a distinct tumor entity that differs from polymorphous low-grade adenocarcinoma (PLGA) by location (ie, most often arising on the tongue), by prominent nuclear clearing, alterations of the PRKD gene family and clinical behavior with frequent metastases at the time of presentation of the primary tumor. Early metastatic disease seen in most cases of CAMSG associated with indolent behavior makes it a unique neoplasm among all low-grade salivary gland tumors. Salivary glands may give rise to a wide spectrum of different tumors. They are often diagnostically challenging as morphological features often overlap between different entities. Although conventional morphology in combination with immunohistochemical findings still provide the most important clues for diagnosis, recent advances in molecular pathology offer new diagnostic tools in investigating the differential diagnosis, as well as providing potentially valuable prognostic indicators. In the last two decades, several new salivary gland tumor entities have been described, namely MASC, SPA and CAMSGs.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2019Open AccessAuthors:Morad Aaboud; Alexander Kupco; Stefan Schmitt; Ahmed Bassalat; Matej Melo; Marjorie Shapiro; Grigore Tarna; Till Eifert; Maximiliano Sioli; Nello Bruscino; +816 moreMorad Aaboud; Alexander Kupco; Stefan Schmitt; Ahmed Bassalat; Matej Melo; Marjorie Shapiro; Grigore Tarna; Till Eifert; Maximiliano Sioli; Nello Bruscino; Toshi Sumida; Andrei Snesarev; Edson Carquin; Mohamad Kassem Ayoub; Yanlin Liu; Paolo Mastrandrea; Liaoshan Shi; José Maneira; Daniela Bortoletto; Tatsuya Masubuchi; Danilo Enoque Ferreira de Lima; Joaquin Poveda; Krzysztof Korcyl; Tatiana Lyubushkina; Christian Grefe; Konstantin Toms; Alberto Valero; Antonio Policicchio; Efe Yigitbasi; Sergey Karpov; Pavol Strizenec; Leigh Schaefer; Marcel Vos; Evelin Meoni; Caterina Doglioni; Masahiro Kuze; Katherine Pachal; Davide Costanzo; Giuliano Gustavino; Mateusz Dyndal; Daniele Zanzi; Alexey Ezhilov; Miguel Arratia; David Paul Yallup; Alena Loesle; Liron Barak; Giuseppe Iacobucci; Benedetto Gorini; Harald Fox; Sergio Grancagnolo; Hok Chuen Cheng; Nico Madysa; Joshua Wyatt Smith; Alessandro Tricoli; Michele Faucci Giannelli; Jana Faltova; Stewart Patrick Swift; Mark Oreglia; Francesco De Lorenzi; Ozan Arslan; Hatice Duran Yildiz; Nicolo Vladi Biesuz; Juan Terron; Stefano Camarda; Maximilian Swiatlowski; Nikolaos Konstantinidis; Osamu Jinnouchi; Hartmut Sadrozinski; Yuya Kano; Daniel Camarero Munoz; Fangzhou Zhang; Manuella Vincter; Markus Elsing; Antony Fray; Paolo Massarotti; Lorenzo Rossini; Giulia Di Gregorio; Francois Corriveau; Karel Smolek; Petr Tas; Ana Rosario Cueto Gomez; Brian Petersen; Victor Solovyev; Bijan Haney; Sinead Farrington; Mauro Villa; Vladimir Cindro; Philip Sommer; Shunsuke Honda; M. Franklin; Yang Qin; Knut Zoch; Susumu Oda; Christian Gutschow; Masahiko Saito; Eva Hansen; Matt Zhang; Adam Bailey; Tomas Jakoubek; Matthias Danninger; Serhat Istin; Mazuza Ghneimat; Goeran Jarlskog; Alessandro De Salvo; Yury Smirnov; Alejandro Alonso; Emma Winkels; Emmanuel Le Guirriec; Andrey Ryzhov; Pier-Olivier Deviveiros; Andres Pacheco Pages; Michael Begel; Allen Mincer; Ljiljana Morvaj; Grazia Cabras; Catalin Agheorghiesei; Roland Jansky; Uwe Bratzler; Claire David; Maria Josefina Alconada Verzini; Romain Kukla; Pawel Klimek; Clara Troncon; Francesco Guescini; Juan Antonio Garcia Pascual; Chunhui Chen; Ivo van Vulpen; Elizaveta Shabalina; Guillaume Unal; Yu Zhang; Zhiqing Zhang; Karishma Sekhon; Gabriele Chiodini; Thorwald Klapdor-kleingrothaus; Frederik Ruehr; Liza Mijović; Harish Potti; Scott Snyder; Rostislav Konoplich; Sarah Heim; Giuseppe Lerner; Stefano Veneziano; Andrey Kiryunin; Laura Barranco Navarro; Leonid Serkin; Dengfeng Zhang; Sergei Smirnov; Babar Ali; Andrej Filipcic; Mario Lassnig; Liang Li; Jonathan Butterworth; Melissa Ridel; Geoffrey Mullier; Kun Liu; Christian Ohm; James Shank; Robert Astalos; Eram Rizvi; Eirik Gramstad; Steven Schramm; Yasuhiro Makida; Ana Paula Pereira Peixoto; Cristiano Alpigiani; Qi Zeng; Nabila Wahab Shaikh; Tibor Zenis; Fabio Cardillo; K. K. Gan; Steffen Henkelmann; Stefano Terzo; Ewelina Lobodzinska; Junji Tojo; Louise Heelan; Giancarlo Panizzo; Muhammad Alhroob; Hans Peter Beck; Katharine Leney; Ryan White; Paolo Camarri; Rafal Staszewski; Elena Rocco; John Rutherfoord; L. L. Ma; Giuseppe Avolio; Gianluca Alimonti; Yang Yang; Chaowaroj Wanotayaroj; Luca Colasurdo; Luc Goossens; Nadezda Proklova; Masato Aoki; Yasushi Nagasaka; Petr Andreevich Gorbounov; Simen Hellesund; Jens Weingarten; Marco Valente; Didier Ferrere; Ina Carli; Sofia Chouridou; Hideyuki Oide; Marcello Bindi; Sandro Palestini; Andrea Ventura; Anna Kaczmarska; Tomas Davidek; Monika Wielers; Yang Li; Domizia Orestano; Nico Giangiacomi; Garabed Halladjian; Alessandro La Rosa; Lawrence Lee; Yaquan Fang; Kevin Varvell; Nils-Arne Rosien; Andrew Pilkington; Claus Goessling; Trine Poulsen; Enrico Junior Schioppa; Arnaud Lucotte; Laura Gonella; Esteban Fullana Torregrosa; Katsuo Tokushuku; Ruchika Nayyar; Rosa Simoniello; Tobias Golling; Kristin Lohwasser; Iouri Naryshkin; Vasiliki Kouskoura; Weiming Yao; Simone Michele Mazza; Patrawan Pasuwan; Frank Ellinghaus; Steven Goldfarb; Valerie Susanne Lang; Arwa Bannoura; Judita Mamuzic; Pavel Staroba; Marcela Mikestikova; Tatyana Kharlamova; Emily McDonald; Jian Cong Zeng; Francisco Alonso; Chris Hays; Craig Sawyer; Pawel Bruckman de Renstrom; Carlos Lacasta; Paolo Morettini; Wolfgang Walkowiak; Kyle Cranmer; Kuan-yu Lin; Joseph Reichert; Vincenzo Canale; Saskia Falke; Krzysztof Wozniak; Claire Antel; Joern Lange; Sandro De Cecco; Silvia Biondi; Julien Donini; Bernhard Meirose; James Robinson; Calin Alexa; Sophie Trincaz-Duvoid; Giada Mancini; Carl Suster; Antonio Ereditato; Wade Cameron Fisher; Marina Rotaru; Aidan Grummer; Petr Balek; Nicolas Morange; Per Johansson; Massimo Della Pietra; Riccardo-Maria Bianchi; Alison Lister; Christos Leonidopoulos; Laura Perini; Dirk Sammel; Giuseppe Callea; Miaoran Lu; Marc-Andre Pleier; Vitaliano Chiarella; Mariusz Przybycien; Petr Hamal; Artur Trofymov; Antoine Marzin; Trisha Farooque; Alan Litke; Frank Winklmeier; Mihai Caprini; Christian Weiser; Florencia Luciana Castillo; Helmut Wolters; Iacopo Vivarelli; Jahred Adelman; Wendy Taylor; Ning Zhou; Koji Terashi; Fabio Cerutti; Paul Glaysher; Emma Torró Pastor; Thomas Trefzger; Alexey Zhemchugov; Baptiste Ravina; Rachel Maria Avramidou; Stephen Hillier; Mohammed Ezzi; Sten Hellman; Wing Sheung Chan; Phillip Urquijo; Vakhtang Kartvelishvili; Lorenzo Massa; Benedict Tobias Winter; Fabian Thiele; Oscar Estrada Pastor; Daniel Lellouch; Aliaksei Hrynevich; Spyridon Argyropoulos; Sergey Senkin; Frederic Deliot; Takuya Nobe; Farida Fassi; Sahal Yacoob; Giuseppe Francesco Tartarelli; Anton Wolf; Farid Ould-Saada; Rachik Soualah; Gilberto Giugliarelli; Wenhao Xu; Artem Maevskiy; Christoph Falk Anders; Roberto Di Nardo; Marcus De Beurs; Marilea Reale; Michal Svatos; Yulia Rodina; Dimitrii Krasnopevtsev; Pingchuan Zhao; Marino Romano; Liang Guan; Peter Loch; Giovanna Cottin; Weimin Song; Heather Gray; Martin Nagel; Stephen Burke; Alexander Held; Paul Thompson; Edward Moyse; Jyoti Prakash Biswal; Jorn Grosse-Knetter; Kohei Yorita; Arno Straessner; Elizabeth Gallas; Evgenia Cheremushkina; Evelyn Thomson; Sergio Calvente Lopez; Oxana Smirnova; Bjarne Stugu; Adam Trzupek; Yoram Rozen; Fabien Jeanneau; Sau Lan Wu; Nikita Smirnov; Ryu Sawada; Michel Lefebvre; Ondrej Penc; Alexandra Tudorache; Nicholas Stuart Dann; Tomasz Bold; Ismet Siral; Andreas Kugel; Andrew Mehta; Arnaud Duperrin; Archil Durglishvili; Craig Buttar; Soumya Mohapatra; Claude Leroy; Dominik Derendarz; Pavel Tsiareshka; Trevor Vickey; Claire Gwenlan; Sergey Peleganchuk; Kristian Gregersen; Andreas Warburton; Andrew Blue; Marco Rimoldi; Peter Johannes Falke; Vadim Bednyakov; Fernando Barreiro; Peter Watkins; Mihail Chizhov; Veronica Fabiani; Santiago González de la Hoz; Xiangyang Ju; Klaus Moenig; Sylvain Tisserant; Alessandra Camplani; Krisztian Peters; David DeMarco; Julien Caudron; Ziyu Guo; Michal Marcisovsky; Ming Chung Chu; Juerg Beringer; Edoardo Maria Farina; Hugh Williams; Patrick Czodrowski; Elias Coniavitis; Diane Cinca; Juan Antonio Aguilar Saavedra; Mykhailo Lisovyi; Aaron White; Michal Suk; Michele Livan; Tamar Djobava; Ladislav Chytka; Pierre-Antoine Delsart; Ivan Sykora; Enrico Tassi; Iwona Grabowska-Bold; Sara Alderweireldt; Luigi Longo; Helio Takai; Patricia Conde Muiño; Johannes Erdmann; Anna Lipniacka; Serkant Ali Cetin; Fabrizio Trovato; Javier Montejo Berlingen; Laurent Schoeffel; Asma Hadef; Jiri Hejbal; Alexandros Marantis; Jean-Francois Arguin; Stefan Richter; Cheuk Yee Lo; Magda Anna Chelstowska; Nicola Orlando; Roger Jones; Marc Escalier; Salvatore Bruno; Giulia Gonella; Sarah Jones; Elisabetta Pianori; Maciej Trzebinski; Nicolas Berger; Guenter Duckeck; Dominik Duda; Sebastien Prince; Alison Elliot; Zuzana Rurikova; Khilesh Pradip Mistry; Jaroslav Guenther; Robert Stanek; Diego Casadei; Minghui Liu; Yuta Okazaki; Calliope Louisa Sotiropoulou; Tomoya Iizawa; Victor Araujo Ferraz; Vladimir Tikhomirov; Umberto De Sanctis; Per Edvin Sidebo; Eftychia Tzovara; Dale Charles Abbott; Werner Spolidoro Freund; Alessandro Calandri; Remi Lafaye; James Broughton; Ralf Hertenberger; Giacomo Artoni; Christophe Raymond Goudet; Oliver Ricken; Patrick Rieck; Sandrine Laplace; Sergey Burdin; Rotem Barnea; Ewan Hill; Andre Sopczak; Emmanuel Sauvan; Dominik Krauss; Jonas Strandberg; Salah-eddine Dahbi; Antonios Leisos; Simone Monzani; Kathleen Whalen; Francesco Giuli; Roman Lysak; Paolo Giromini; Leszek Adamczyk; Jason Nielsen; Thomas Koffas; Marcella Bona; Beojan Stanislaus; Gianluca Introzzi; Natascha Savic; Wasikul Islam; Otmar Biebel; Fares Djama; Federico Sforza; Jonathan Bortfeldt; Eleni Myrto Asimakopoulou; Yun Tian; Romain Madar; Phillip Allport; Nicolas Ellis; Jan Godlewski; Jiri Kroll; Benjamin Trocmé; Stephen Watts; Will Davey; Yann Coadou; Wladyslaw Dabrowski; Cristinel Diaconu; Clement Helsens; Hongbo Zhu; Swagato Banerjee; Stephen Lloyd; Alessandra Betti; Peter van Gemmeren; Alberto Aloisio; Vincent Pascuzzi; Driss Benchekroun; Martin Aleksa; Ilija Vukotic; Evgeniy Khramov; James Monk; Michel Vetterli; Marco Vanadia; Takahiko Kondo; Bruno Lenzi; Aleandro Nisati; Gerjan Bobbink; Paul Dervan; Stefania Spagnolo; Dave Charlton; Robert Les; Marcella Capua; Jochen Jens Heinrich; Valentina Tudorache; Stephen Jiggins; Kunlin Han; Shunsuke Adachi; Amy Selvi Tee; Giulio Aielli; Susana Cabrera Urbán; Paolo Calafiura; Pavel Starovoitov; Lorenzo Feligioni; Vladimir Sulin; Meghan Frate; Camilla Di Donato; Ludovic Michel Scyboz; Bakar Chargeishvili; Eric Edward Corrigan; Kendall Reeves; Gideon Bella; Alexandre Rozanov; M. J. Shochet; Ewa Stanecka; Norman Gee; Efstathios Karentzos; Katharina Behr; Jozsef Toth; Peter Onyisi; Remi Zaidan; Tim Michael Heinz Wolf; Fang-ying Tsai; Irinel Caprini; Abraham Seiden; Martina Laura Ojeda; Gonzalo Enrique Orellana; Marcos Vinicius Silva Oliveira; Fabrizio Napolitano; Arka Santra; Jan Kretzschmar; Stefano Rosati; Janet Dietrich; Gen Kawamura; Angel Campoverde; Oleg Brandt; Antinea Guerguichon; James Walder; Torsten Paul Ake Åkesson; Namig Javadov; Milene Calvetti; Louis Guillaume Gagnon; Paul Jackson; Matteo Franchini; Maurizio De Santis; Christian Schmitt; Ren-Jie Wang; Hasko Stenzel; Sebastian Grinstein; Aidan Robson; Paolo Sabatini; Flavia De Almeida Dias; Marco Delmastro; Jeroen Schouwenberg; Song-Ming Wang; Danijela Bogavac; Mikhail Levchenko; Paul Miyagawa; Nataliia Zakharchuk; Valerio Dao; Kerstin Jon-And; Laurent Serin; Andrea Coccaro; Milos Lokajicek; Christos Vergis; Jiangyong Jia; Yusheng Wu; Mathieu Benoit; Georges Azuelos; Markus Cristinziani; Soshi Tsuno; Athanasios Manousos; Yee Chinn Yap; Jos Vermeulen; Sune Jakobsen; Philipp Mogg; Marek Palka; Carl Gwilliam; Osamu Sasaki; Roberto Iuppa; Yohei Yamaguchi; Anjishnu Bandyopadhyay; Philipp Horn; Syed Haider Abidi; Nishu Nishu; Jose Guillermo Panduro Vazquez; Ilia Ravinovich; Uladzimir Kruchonak; Alessia Murrone; Gerald Oakham; Annick Lleres; Nathalie Besson; Matthias Saimpert; Janusz Chwastowski; Marco Sessa; Takanori Kono; Jens Janssen; Antonio Onofre; Arthur Eugen Bolz; Nikolina Ilic; Jolanta Olszowska; Elisabeth Schopf; Vakhtang Tsulaia; Nicolin Govender; Martine Bosman; Danuta Kisielewska; Ilkay Turk Cakir; Victor Maleev; Michele Pinamonti; Marta Losada; Marija Vranjes Milosavljevic; Lee Sawyer; Joaquin Hoya; Caterina Marcon; Victor Kukhtin; Georges Aad; Hyungsuk Son; Michaela Queitsch-Maitland; George Redlinger; Fred Wickens; Ki Lie; Marcel Weirich; Matteo Negrini; Filipe Veloso; Sabrina Groh; Lucia Masetti; Thomas Billoud; Akshat Puri; Francesco Maria Follega; Vadim Gratchev; Tadej Novak; Nektarios Benekos; Miguel Villaplana Perez; Henri Bachacou; Alessandro Cerri; Massimo Lazzaroni; Edward Diehl; Jan-Hendrik Arling; Julie Kirk; Andrey Kamenshchikov; Rui Wang; Ruggero Turra; Andrea Knue; Steven Worm; Hajime Nanjo; Christian Oliver Sander; Eduard Simioni; Hongtao Yang; Matteo Scornajenghi; Valerio Vercesi; Lewis James Armitage; Khalil Bouaouda; Sigve Haug; Christina Potter; Fuqiang Wang; Benoit Lefebvre; Aparajita Dattagupta; Sourav Sen; Hans-Christian Schultz-Coulon; Yuji Yamazaki; Peter Berta; Murrough Landon; Fabrice Hubaut; Leonid Kurchaninov; Dimitrios Iliadis; Alexey Anisenkov; Yanjun Tu; Richard Keeler; Stanislav Nemecek; Frank Filthaut; Guennadi Borissov; Amal Vaidya; Laurent Chevalier; Veronika Magerl; Paola Giannetti; Orhan Cakir; Tomohiro Yamazaki; Javier Llorente Merino; Geoffrey Taylor; Anatoli Romaniouk; Alberto Stabile; Stamatios Gkaitatzis; Evgenii Baldin; Serhat Oerdek; Paul Mircea Gravila; Nikola Makovec; Marzieh Bahmani; Konstantinos Bachas; Konstantinos Nikolopoulos; Oliver Majersky; Elliot Reynolds; Troels Petersen; Oldrich Kepka; Maximilian Hils; Francesco Ragusa; Haifeng Li; Stephen Gibson; Aimilianos Koulouris; Teng Jian Khoo; Alexi Gongadze; Robert McPherson; Daniel Muenstermann; Jeffrey David Shahinian; Bruce Yabsley; Kilian Rosbach; Philipp Stolte; Tamara Vazquez Schroeder; Royer Edson Ticse Torres; Andrew D. Hamilton; Siqi Yang; Claudia Glasman; Tigran Mkrtchyan; Theodoros Alexopoulos; Paul Philipp Gadow; Leonor Cerda Alberich; Riccardo Vari; Debarati Roy; Tomas Dado; Dave Britton; Vojtech Pleskot; Yuri Kulchitsky; Margherita Primavera; Konstantinos Ntekas; Minyu Feng; Thorsten Wengler; Deepak Kar; Jianming Qian; Frank Merritt; Shyam Balaji; Lydia Brenner; Xin Wu; Nikiforos Nikiforou; Jiri Chudoba; Andrea Formica; Michal Dubovsky; Christos Anastopoulos; James Mueller; Francesca Ungaro; Jonathan David Bossio Sola; Elvedin Tahirovic; Torre Wenaus; Giulio Cornelio Grossi; Abhishek Sharma; Evangelos Kourlitis; Craig Wiglesworth; Antonio Salvucci; Bingxuan Liu; Pascal Pralavorio; Valerio Ippolito; Laura Fabbri; Lydia Roos; Stefania Xella; Radek Novotny; David Lynn; Elizabeth Brost; Martin White; Andrzej Olszewski; Nenad Vranjes; Lamberto Luminari; Peter Kodys; Tim Adye; John Baines; Lara Katharina Schildgen; Adriaan Koenig; Tristan Beau; Lily Asquith; Maria Smizanska; Mattias Ellert; Zoya Karpova; Othmane Rifki; Gunnar Jakel; Walter Hopkins; Werner Wiedenmann; Kazunori Hanagaki; Eric Lancon; Andrzej Smykiewicz; Christine Kourkoumelis; Jana Schaarschmidt;Publisher: American Physical Society (APS)Project: NSERC
A measurement of the associated production of a top-quark pair (tt) with a vector boson (W, Z) in proton-proton collisions at a center-of-mass energy of 13 TeV is presented, using 36.1 fb-1 of integrated luminosity collected by the ATLAS detector at the Large Hadron Collider. Events are selected in channels with two same- or opposite-sign leptons (electrons or muons), three leptons or four leptons, and each channel is further divided into multiple regions to maximize the sensitivity of the measurement. The ttZ and ttW production cross sections are simultaneously measured using a combined fit to all regions. The best-fit values of the production cross sections are σttZ=0.95±0.08stat±0.10syst pb and σttW=0.87±0.13stat±0.14syst pb in agreement with the Standard Model predictions. The measurement of the ttZ cross section is used to set constraints on effective field theory operators which modify the ttZ vertex.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2015Open AccessAuthors:Jiří Vohánka; Mir Faizal;Jiří Vohánka; Mir Faizal;Publisher: American Physical Society (APS)
In this paper, we will analyze three-dimensional supersymmetric Yang-Mills theory coupled to matter fields in $SIM(1)$ superspace formalism. The original theory which is invariant under the full Lorentz group has $\mathcal{N}=1$ supersymmetry. However, when we break the Lorentz symmetry down to $SIM(1)$ group, the $SIM(1)$ superspace will break half the supersymmetry of the original theory. Thus, the resultant theory in $SIM(1)$ superspace will have $\mathcal{N}=1/2$ supersymmetry. This is the first time that $\mathcal{N}=1$ supersymmetry will be broken down to $\mathcal{N}=1/2$ supersymmetry, for a three-dimensional theory, on a manifold without a boundary. This is because it is not possible to use nonanticommutativity to break $\mathcal{N}=1$ supersymmetry down to $\mathcal{N}=1/2$ supersymmetry in three dimensions.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . Article . 2003Open AccessAuthors:Schellenberg, D; Armstrong Schellenberg, J R M; Mushi, A; Savigny de, D; Mgalula, L; Mbuya, C; Victoria, C.G.;Schellenberg, D; Armstrong Schellenberg, J R M; Mushi, A; Savigny de, D; Mgalula, L; Mbuya, C; Victoria, C.G.;Country: Tanzania (United Republic of)
Objective was to document the prevalence, age-distribution, and risk factors for anaemia in Tanzanian children less than 5 years old,thereby assisting in the development of effective strategies for controlling anaemia. Cluster sampling was used to identify 2417 households at random from four contiguous districts in south-eastern United Republic of Tanzania in mid-1999. Data on various social and medical parameters were collected and analysed. Blood haemoglobin concentrations (Hb) were available for 1979 of the 2131 (93%) children identified and ranged from 1.7 to 18.6 g/dl. Overall, 87% (1722) of children had an Hb <11 g/dl, 39% (775) had an Hb <8 g/dl and 3% (65) had an Hb <5 g/dl. The highest prevalence of anaemia of all three levels was in children aged 6–11 months, of whom 10% (22/226) had an Hb <5 g/dl. However, the prevalence of anaemia was already high in children aged 1–5 months (85% had an Hb <11 g/dl, 42% had an Hb <8 g/dl, and 6% had an Hb <5 g/dl). Anaemia was usually asymptomatic and when symptoms arose they were nonspecific and rarely identified as a serious illness by the care provider. A recent history of treatment with antimalarials and iron was rare. Compliance with vaccinations delivered through the Expanded Programme of Immunization (EPI) was 82% and was notassociated with risk of anaemia. Anaemia is extremely common in south-eastern United Republic of Tanzania, even in very young infants. Further implementation of the Integrated Management of Childhood Illness algorithm should improve the case management of anaemia. However, the asymptomatic nature of most episodes of anaemia highlights the need for preventive strategies. The EPI has good coverage of the target population and it may be an appropriate channel for delivering tools for controlling anaemia and malaria.
- Publication . Other literature type . Article . 2019Open AccessAuthors:Zdenka Ellederova; Sonia del Rincon; Marketa Koncicka; Andrej Susor; Michal Kubelka; Dahui Sun; Charles Spruck;Zdenka Ellederova; Sonia del Rincon; Marketa Koncicka; Andrej Susor; Michal Kubelka; Dahui Sun; Charles Spruck;Publisher: American Society for Microbiology
Cell division cycle (Cdc) kinase subunit (CKS) proteins bind cyclin-dependent kinases (CDKs) and play important roles in cell division control and development, though their precise molecular functions are not fully understood. Mammals express two closely related paralogs called CKS1 and CKS2, but only CKS2 is expressed in the germ line, indicating that it is solely responsible for regulating CDK functions in meiosis. Using cks2(−/−) knockout mice, we show that CKS2 is a crucial regulator of maturation-promoting factor (MPF; CDK1-cyclin A/B) activity in meiosis. cks2(−/−) oocytes display reduced and delayed MPF activity during meiotic progression, leading to defects in germinal vesicle breakdown (GVBD), anaphase-promoting complex/cyclosome (APC/C) activation, and meiotic spindle assembly. cks2(−/−) germ cells express significantly reduced levels of the MPF components CDK1 and cyclins A1/B1. Additionally, injection of MPF plus CKS2, but not MPF alone, restored normal GVBD in cks2(−/−) oocytes, demonstrating that GVBD is driven by a CKS2-dependent function of MPF. Moreover, we generated cks2(cks1/cks1) knock-in mice and found that CKS1 can compensate for CKS2 in meiosis in vivo, but homozygous embryos arrested development at the 2- to 5-cell stage. Collectively, our results show that CKS2 is a crucial regulator of MPF functions in meiosis and that its paralog, CKS1, must be excluded from the germ line for proper embryonic development.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product. - Publication . ArticleOpen Access EnglishPublisher: Published by Elsevier Inc.
- Publication . Preprint . 1995Open Access EnglishAuthors:Mares, J.; Friedman, E.; Gal, A.; Jennings, B. K.;Mares, J.; Friedman, E.; Gal, A.; Jennings, B. K.;Project: NSERC
Strong interaction level shifts and widths in $\Sigma^-$ atoms are analyzed by using a $\Sigma$ nucleus optical potential constructed within the relativistic mean field approach. The analysis leads to potentials with a repulsive real part in the nuclear interior. The data are sufficient to establish the size of the isovector meson--hyperon coupling. Implications to $\Sigma$ hypernuclei are discussed. Comment: 18 pages, RevTex, 4 uuencoded figures, subm. Nucl.Phys.A
- Publication . Article . 1997Open AccessAuthors:Graham J. Schapel; Sheila J. Wallace; Gillian S. Gordon;Graham J. Schapel; Sheila J. Wallace; Gillian S. Gordon;Publisher: Elsevier BV
A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales. Of 79 patient treatments with LTG and 86 with GVG, 42 patients were treated with add-on LTG, 52 with add-on GVG and 20 with both drugs simultaneously. A Kaplan-Meier curve, applied to each of the two index drugs, indicated that 71 and 62% of patients would be expected to continue taking LTG or GVG, respectively after 40 months. Improved seizure control (≥ 50%) at the time of audit was seen in 65% of LTG and 58% of GVG patient treatments for all epilepsy syndromes, but there was a higher proportion of patients with generalized epilepsy improved by LTG (28/41, 68%) than that improved by GVG (8/20, 40%), and only those with generalized epilepsy treated with LTG became seizure free (8/38, 21%). Similar proportions of patients discontinued LTG (16%) and GVG (15%) due to an adverse experience, but a higher proportion discontinued GVG (18%) compared with LTG (6%) because of lack of efficacy. This study supports the relative clinical effectiveness of LTG and GVG in the real world, where children with severe epilepsy are treated in clinical practice and serves to generate hypotheses to enable design of prospectively controlled trials, which should enable more rational use of these two drugs in the paediatric population with epilepsy.
Average popularityAverage popularity In bottom 99%Average influencePopularity: Citation-based measure reflecting the current impact.Average influence In bottom 99%Influence: Citation-based measure reflecting the total impact.add Add to ORCIDPlease grant OpenAIRE to access and update your ORCID works.This Research product is the result of merged Research products in OpenAIRE.
You have already added works in your ORCID record related to the merged Research product.